- Trials with a EudraCT protocol (2,186)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (82)
2,186 result(s) found for: Radiotherapy.
Displaying page 1 of 110.
| EudraCT Number: 2019-001711-23 | Sponsor Protocol Number: ET19-084 | Start Date*: 2020-02-03 |
| Sponsor Name:Centre Léon Bérard | ||
| Full Title: CICA-RT – Phase III randomized multicenter study evaluating Cicaderma® ointment efficacy versus the current practice of each center for the radiation dermatitis prevention in patients with non-meta... | ||
| Medical condition: Breast adenocarcinoma treated with post-operative radiotherapy Post-operative breast cancer radiotherapy | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2012-001879-37 | Sponsor Protocol Number: ArtscanIII | Start Date*: 2013-03-05 | ||||||||||||||||
| Sponsor Name:Department of Oncology, Skåne University Hospital Lund | ||||||||||||||||||
| Full Title: A randomized multicenter phase III study of cisplatin plus radiotherapy compared to cetuximab plus radiotherapy in locally advanced head and neck cancer | ||||||||||||||||||
| Medical condition: Stage III and IV head and neck squamous cell cancer (HNSCC) without radiographic signs of distant metastases aimed for radiotherapy with curative intent | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-001216-19 | Sponsor Protocol Number: | Start Date*: 2014-11-13 |
| Sponsor Name:NHS Greater Glasgow & Clyde [...] | ||
| Full Title: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose e... | ||
| Medical condition: glioblastoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-000833-40 | Sponsor Protocol Number: CCR4502 | Start Date*: 2016-10-07 |
| Sponsor Name:The Institute of Cancer Research | ||
| Full Title: Phase I ’run in’ study followed by randomised phase II trial testing intra-tumoural hydrogen peroxide as a radiation sensitizer in patients with locally advanced/recurrent breast cancer in terms of... | ||
| Medical condition: Women with locally advanced/recurrent breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-020174-42 | Sponsor Protocol Number: ZonMw11510009 | Start Date*: 2011-11-04 |
| Sponsor Name:ZonMw | ||
| Full Title: Dexamethasone for the prevention of a pain flare after palliative radiotherapy for painful bone metastases: a multicenter double-blind placebo-controlled randomized study | ||
| Medical condition: Bone metastases | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-004133-27 | Sponsor Protocol Number: DAHANCA30 | Start Date*: 2016-04-18 |
| Sponsor Name:Århus Universitetshospital Afd for Eksp. Klinisk onkologi | ||
| Full Title: A randomized non-inferiority trial of hypoxia-profile guided hypoxic modification with nimorazole during radiotherapy/chemoradiotherapy of squamous cell carcinoma of the head and neck | ||
| Medical condition: Patients with squamous cell carcinoma of the head and neck | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-002122-20 | Sponsor Protocol Number: 0460 | Start Date*: 2018-06-06 |
| Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. med. Markus F. Neurath | ||
| Full Title: Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE) | ||
| Medical condition: Metastatic head and neck squamous cell carcinoma (LLT, 20.1) 10060121 (LLT, 20.1) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-004425-13 | Sponsor Protocol Number: PP01 | Start Date*: 2016-01-22 | |||||||||||
| Sponsor Name:Skåne University Hospital, Department of Oncology | |||||||||||||
| Full Title: Prospective evaluation of 68-Ga-PSMA-PET and early PSA kinetics during salvage radiotherapy for personalizing the management of men with relapse of prostate cancer after radical prostatectomy. | |||||||||||||
| Medical condition: Patients with prostate cancer, with a PSA recurrence of ˃ 0.2 ng/ml after prostatectomy, and who are going to receive radiotherapy to the prostate bed. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-003980-38 | Sponsor Protocol Number: ML 21800 | Start Date*: 2008-09-22 |
| Sponsor Name:Roche Slovensko s.r.o. | ||
| Full Title: An open label study of the effect of Xeloda and radiotherapy on pathological response rate in patients with locally advanced rectal cancer. | ||
| Medical condition: Locally advanced rectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SK (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2004-000358-21 | Sponsor Protocol Number: D7919C00706 (ZD1839IL/0706) | Start Date*: 2004-10-06 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiother... | ||
| Medical condition: Untreated, unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-004031-37 | Sponsor Protocol Number: 17.14 | Start Date*: 2017-12-07 |
| Sponsor Name:Department of oncology, Odense University Hospital | ||
| Full Title: A multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo® (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients rece... | ||
| Medical condition: Eligible patients will have a diagnosis of cervical cancer, and be scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks. P... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: DK (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-020621-40 | Sponsor Protocol Number: OCTO_021 | Start Date*: 2010-09-30 |
| Sponsor Name:The University of Oxford | ||
| Full Title: SONATINA: A Phase II Multi-Centre Randomised Controlled Study of Nelfinavir Addition to Radiotherapy Treatment in Neo-Adjuvant Therapy for Rectal Cancer | ||
| Medical condition: inoperable rectal cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-002028-41 | Sponsor Protocol Number: HPX-2011-003 | Start Date*: 2014-01-17 | |||||||||||
| Sponsor Name:Oxford University Hospitals NHS Trust | |||||||||||||
| Full Title: A study to determine regional lung function in patients with Non-small cell lung cancer (NSCLC) undegoing radiotherapy using hyperpolarised xenon gas MR imaging | |||||||||||||
| Medical condition: Non-small cell lung cancer. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2004-002547-27 | Sponsor Protocol Number: OP/CD001 | Start Date*: 2005-09-03 |
| Sponsor Name:University of Bristol | ||
| Full Title: Combined Immunosuppression and Radiotherapy in Thyroid Eye Disease | ||
| Medical condition: Thyroid Eye Disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2010-018720-12 | Sponsor Protocol Number: pb01 | Start Date*: 2010-04-22 |
| Sponsor Name:Swedish Pituitary Study group | ||
| Full Title: Behandling med kabergolin hos patienter med ACTH-beroende Cushing´s syndrom (treatment with cabergoline in patients with ACTH-dependent Cushing´s syndrome | ||
| Medical condition: A) Men and women aged 18 to 75 years with hypercortisolism due to ACTH-dependent Cushing's syndrome will be treated in the period between diagnosis and planned surgery or radiation therapy. B) Men... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-003149-17 | Sponsor Protocol Number: NSCLC-TRT-Avastin | Start Date*: 2006-12-04 |
| Sponsor Name:VU University Medical Center | ||
| Full Title: Phase I study of concurrent with involved-field thoracic radiotherapy for inoperable non-squamous cell lung cancer, followed by both concurrent and maintenance Bevacizumab | ||
| Medical condition: Patients with locally advanced (stages II-IIIB) non-small cell lung cancer who are eligible for high-dose radiotherapy following the completion of induction systemic chemotherapy. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-002097-61 | Sponsor Protocol Number: DAHANCA 19 | Start Date*: 2007-07-26 | |||||||||||
| Sponsor Name:Danish Head and Neck Cancer Group | |||||||||||||
| Full Title: Undersøgelse af betydningen af EGFr antistoffet Zalutumumab for effekten af strålebehandling til patienter med primært planocellulært hoved-hals karcinom. | |||||||||||||
| Medical condition: Squamous cell carcinomas of the Head and Neck treated with primary radiotherapy/kemoradiotherapy and randomized to the IMP in question (zalutumumab). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004952-13 | Sponsor Protocol Number: DART | Start Date*: 2020-12-14 | |||||||||||
| Sponsor Name:University Hospital Ghent | |||||||||||||
| Full Title: Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) | |||||||||||||
| Medical condition: - Prostate cancer patients with a biochemical recurrence following primary therapy - Hormone-sensitive - Up to 5 metastases on PSMA PET-CT | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: BE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003177-26 | Sponsor Protocol Number: RT2019-13 | Start Date*: 2020-02-05 |
| Sponsor Name:UMCG | ||
| Full Title: Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy | ||
| Medical condition: Patients with biochemical recurrence after primary treatment of prostate cancer presenting with ≤4 metastases | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002517-18 | Sponsor Protocol Number: PROICM2020-04GAB | Start Date*: 2020-10-19 | |||||||||||
| Sponsor Name:Institut régional du cancer de Montpellier (ICM) | |||||||||||||
| Full Title: Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with ... | |||||||||||||
| Medical condition: Locally advanced adenocarcinoma of pancreas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
